Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 80

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 80
---
 stockholders from bringing a lawsuit against our
directors and officers for breaches of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our
directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder’s
investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers
as required by these indemnification provisions.

Our management collectively owns a substantial percentage of our Common Stock.

Based on the provisions for determining beneficial
ownership in accordance with Rule 13d-3 and Item 403 of Regulation S-K under the Exchange Act, immediately after this Offering, our officers
and directors will own or exercise control of approximately 24% of the voting power of our outstanding Common Stock. As a result, investors
may be prevented from affecting matters involving our Company, including:

| ● | the composition of our Board and, through it, any determination with respect to our business direction and policies, including the appointment and removal of officers; |
| ● | any determinations with respect to mergers or other business combinations;                                                                                              |
| ● | our acquisition or disposition of assets; and                                                                                                                           |
| ● | our corporate financing activities.                                                                                                                                     |

Furthermore, this concentration of voting power could
have the effect of delaying, deterring, or preventing a change of control or other business combination that might otherwise be beneficial
to our stockholders. This significant concentration of share ownership may also adversely affect the trading price for our Common Stock
because investors may perceive disadvantages in owning stock in a company that is controlled by a small number of stockholders.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our Common Stock will depend
in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts
do not currently, and may never, publish research on our Company. If no or only very few securities analysts commence coverage of us,
or if industry analysts cease coverage of us, the trading price for our Common Stock would be negatively affected. If one or more of the
analysts who cover us downgrade our Common Stock or publish inaccurate or unfavorable research about our business, our Common Stock price
would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our
Common Stock could